Physician profile
Fe A Inocentes
NPI 1851306542
$9,658.91
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,243 · 2020: $2,153 · 2021: $3,984 · 2022: $1,249 · 2024: $29.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,673.25 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $1,326.29 | 2021 | |
| Novo Nordisk INC | $787.92 | 2019-2022 | |
| Abbvie INC. | $738.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $465.32 | 2019-2022 | |
| Lilly USA, LLC | $448.84 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.92 | 2019-2022 | |
| Amarin Pharma, INC. | $351.11 | 2019-2021 | |
| Astellas Pharma US INC | $348.76 | 2019-2022 | |
| Amgen INC. | $340.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $265.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $221.24 | 2019-2021 | |
| Pfizer INC. | $200.30 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $192.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.96 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fe Inocentes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.